Refractory severe connective tissue disease thrombocytopenia: Is rituximab treatment effective and safe?

Annals of the Rheumatic Diseases

Volumn 68, Issue 6, 2009, Pages 1077-1078

  Zheng, W J ^a   Zhang, X ^a   Wang, Q ^a   Xu, D ^a   Zeng, X F ^a   Zhang, F C ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ASEPTIC NECROSIS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FEMUR HEAD NECROSIS; HUMAN; HYPERTENSION; IMMUNOCOMPROMISED PATIENT; LETTER; LIVER FUNCTION; LIVER INJURY; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REFRACTORY SEVERE CONNECTIVE TISSUE DISEASE THROMBOCYTOPENIA; SECONDARY INFECTION; SIDE EFFECT; SJOEGREN SYNDROME; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; CONNECTIVE TISSUE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 67449139113     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.098293     Document Type: Letter

References (10)

1. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-334 (Pubitemid 351281266)
2. Salama A, Schneider U, Dörner T. Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis 2008;67:894-895 (Pubitemid 351829398)
3. Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol 2006;133:53-55 (Pubitemid 43195957)
4. Ahn ER, Lander G, Bidot CJ, Jy W, Ahn YS. Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 2005;78:127-129 (Pubitemid 40194105)
5. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-496
6. Beardsley DS. ITP in the 21st century. Hematology Am Soc Hematol Educ Program 2006:402-407
7. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol 2007;14:642-646
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
9. Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008;93:930-933 (Pubitemid 351821733)
10. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-1545 (Pubitemid 41742472)